×

Atara Bio to Participate in the Morgan Stanley Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that Isaac Ciechanover, M.D., the Company's President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 1:05 p.m. ET. The conference will be held at The Grand Hyatt Hotel in New York, NY.

A live webcast of the discussion will be available by visiting the Investors section of the Atara Bio website at www.atarabio.com. An archived replay of the webcast will be available on the Company's website for 14 days following the event.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, with an initial focus on immunotherapy and oncology. Atara Bio's programs include T-cell product candidates and molecularly targeted product candidates. The T-cell product candidates include EBV-CTL, CMV-CTL, and WT1-CTL and harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The molecularly targeted product candidates include STM 434. These product candidates target activin and myostatin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications.

INVESTOR & MEDIA CONTACT: Investors: Steve Klass 212-213-0006 x331 sklass@burnsmc.com Media: Justin Jackson 212-213-0006 x327 jjackson@burnsmc.com

Source:Atara Biotherapeutics, Inc.